XOMA Royalty Corporation Announces Participation at Conference
XOMA Royalty Corporation (NASDAQ: XOMA), a leading biotech royalty aggregator, is proud to announce its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. This notable event will be held virtually, making it accessible for attendees from all over. The conference is scheduled for February 11-12, and XOMA’s executives are excited to share their insights.
Key Presentations by XOMA’s Executive Team
Owen Hughes, the Chief Executive Officer of XOMA, will engage in a fireside chat alongside Brad Sitko, Chief Investment Officer, on the first day of the conference, February 11. Their discussion is set for 3:20 PM ET, and they will cover vital topics that reflect the company’s strategic direction and growth potential. Participants eager to hear about the latest developments and insights in biotechnology won’t want to miss out on this session.
Accessing XOMA’s Conference Presentations
For anyone interested in the presentation, XOMA ensures that it can be conveniently accessed online. Attendees can visit their investor relations section on the company’s official website. There will also be a replay available for 90 days after the event, allowing viewers to catch up on any information they might have missed.
About XOMA’s Role in Biotechnology
XOMA Royalty plays a crucial role in the biotechnology industry by aggregating royalties. The company facilitates funding for biotech firms, allowing them to focus on their internal drug candidates and overall corporate growth. By acquiring potential future earnings from pre-commercial and commercial therapeutic candidates, XOMA provides non-dilutive financing options. This setup enables sellers to secure necessary resources without sacrificing equity.
Portfolio and Opportunities
The company boasts an extensive and continually growing portfolio of assets, which represent the rights to receive future earnings based on the successful advancement of therapeutic candidates. This unique business model positions XOMA Royalty as a significant player in the biopharmaceutical landscape, supporting innovation and improving health outcomes across diverse therapeutic areas.
Being Part of a Larger Community
Beyond their financial strategies, XOMA is dedicated to the broader goal of enhancing human health. They understand that their success is tied to the success of the companies they support and the patients who rely on innovative therapies. XOMA's commitment to fostering better health through strategic partnerships reflects their core mission.
Contact Information for Inquiries
For those who wish to learn more about XOMA Royalty Corporation and their recent developments, they can reach out to their investor relations team. Juliane Snowden is available to handle investor queries and provide insights into the company’s financial strategies and future endeavors.
Media Inquiries
Alternatively, for media inquiries, Kathy Vincent from KV Consulting & Management can be contacted for additional information related to XOMA's latest activities and presence in upcoming events.
Frequently Asked Questions
What is the purpose of XOMA Royalty's participation in the conference?
XOMA Royalty aims to share insights about its business strategies and the advancements in biotechnology that it supports.
Who will be speaking for XOMA Royalty at the conference?
The Chief Executive Officer, Owen Hughes, and Chief Investment Officer, Brad Sitko, will represent the company during the presentation.
How can I access XOMA's presentation online?
XOMA will provide access to their presentation through the investor relations section of their official website, with a replay available for 90 days post-event.
What types of assets does XOMA Royalty manage?
XOMA manages rights to future earnings related to various therapeutic candidates, enhancing their portfolio through strategic acquisitions.
How does XOMA support biotechnology companies?
XOMA provides non-dilutive funding to biotech companies, allowing them to focus on developing their drug candidates without losing equity stakes.
